Company Research Report: COUR Pharmaceuticals
Company Overview
Name, Mission of the Company
COUR Pharmaceuticals is committed to developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated diseases.
Founding Information
Founded by: John J. Puisis
When: No information is available
Key People in the Company
- Founder & Former President and CEO: John J. Puisis
- New CEO: Dannielle Appelhans
- Chief Medical Officer: Paul M. Peloso, MD
- Chief Financial Officer: Brian C. Bock
- Chief People Officer: Sarah Longoria
- VP, Immunology & Innovation: Adam Elhofy, PhD
- VP, Technical Development: Robert Hodge
- VP, Manufacturing and Supply Chain: Lori Jester
- Head of Clinical Operations: Karthi Natarajan
- VP, Controller: Tony Mitchell
Headquarters
Location: Chicago, Illinois, USA
Number of Employees
No information is available
Revenue of the Company
No information is available
What the Company is Known For
COUR Pharmaceuticals is known for developing first-in-class, disease-modifying therapies utilizing their immune-modifying nanoparticle platform to treat the root cause of immune and inflammatory conditions.
Products
Overview
COUR Pharmaceuticals offers a range of investigational therapies aimed at treating autoimmune diseases by inducing antigen-specific immune tolerance.
Key Products
CNP-101/TAK-101
- Indication: Celiac Disease
- Description: A biodegradable nanoparticle encapsulating gliadin proteins, intended to induce antigen-specific immune tolerance.
- Key Features:
- First investigational agent to achieve antigen-specific immune tolerance in an autoimmune disease.
- Phase 2 trials showed reduced inflammation and intestinal protection in celiac patients.
CNP-106
- Indication: Myasthenia Gravis
- Description: A product targeting immunological root causes to prevent neuromuscular destruction.
- Key Features:
- Antigen-specific investigational therapeutic.
- Reprograms the immune system to address the underlying cause of Myasthenia Gravis.
CNP-103
- Indication: Type 1 Diabetes
- Description: Designed to reprogram the immune system to stop immune-mediated destruction of pancreatic islet cells.
- Key Features:
- Aims to achieve long-term therapeutic efficacy without broad immune suppression.
CNP-104
- Indication: Primary Biliary Cholangitis
- Description: A nanoparticle encapsulating PDC-E2 designed to mitigate immune-mediated destruction in bile ducts.
- Key Features:
- Address underlying dysregulated immune response.
- Received FDA Fast Track designation.
Recent Developments
Leadership Changes
- Leadership Transition: Founder John J. Puisis will transition the CEO role to COO Dannielle Appelhans, effective September 1, 2024.
- Board Changes: John J. Puisis will continue to serve on the Board of Directors and as an advisor through the end of 2024. Dannielle Appelhans has also been appointed to the Board of Directors.
Partnerships
- Takeda Pharmaceuticals: Partnered for CNP-101 for treating Celiac Disease.
- Ironwood Pharmaceuticals: Partnered for CNP-104 targeting Primary Biliary Cholangitis.
Financial Developments
- Series A Financing: Secured $105 million in Series A financing co-led by Lumira Ventures and Alpha Wave Ventures in January 2024.
Appointments
- Tim Walbert: Appointed to the Board of Directors in June 2024.
- Paul M. Peloso, MD: Appointed Chief Medical Officer in May 2024.
Recent Clinical Progress
- Phase 1b/2a Study: Currently enrolling patients in a clinical study for Myasthenia Gravis.
- Product Candidates: Developing new product candidates for Myasthenia Gravis and Type 1 Diabetes.
Conclusion
COUR Pharmaceuticals stands at the forefront of developing innovative therapies for autoimmune and inflammatory diseases with a unique approach centered around antigen-specific immune tolerance. Their recent leadership transition, strategic partnerships, and successful fundraising highlight their ongoing commitment to advancing their clinical programs and expanding their impact on patient care.